.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The EOLIA randomized trial evaluated early venovenous extracorporeal membrane oxygenation in patients with very severe acute respiratory distress syndrome. The trial did not demonstrate a statistically significant reduction in the primary endpoint of 60-day mortality, although mortality was numerically lower with ECMO and a substantial proportion of patients in the control group crossed over to rescue ECMO. This makes the study especially valuable for clinical decision-making because it illustrates both the potential benefit and the complexity of evaluating rescue therapies in critical illness. ECMO should therefore not be treated as a routine escalation step for all patients with severe hypoxaemia. Instead, selection, timing, referral, center expertise, and integration with lung-protective ventilation and prone positioning are crucial. For HCPs, the practical takeaway is that ECMO is best considered within a structured severe-ARDS pathway, with early recognition of patients whose trajectory is deteriorating and timely consultation with an experienced center. This evidence fits the conference’s focus on ECMO capacity-building beyond metro centres and on realistic referral networks for complex respiratory failure.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The EOLIA randomized trial evaluated early venovenous extracorporeal membrane oxygenation in patients with very severe acute respiratory distress syndrome. The trial did not demonstrate a statistically significant reduction in the primary endpoint of 60-day mortality, although mortality was numerically lower with ECMO and a substantial proportion of patients in the control group crossed over to rescue ECMO. This makes the study especially valuable for clinical decision-making because it illustrates both the potential benefit and the complexity of evaluating rescue therapies in critical illness. ECMO should therefore not be treated as a routine escalation step for all patients with severe hypoxaemia. Instead, selection, timing, referral, center expertise, and integration with lung-protective ventilation and prone positioning are crucial. For HCPs, the practical takeaway is that ECMO is best considered within a structured severe-ARDS pathway, with early recognition of patients whose trajectory is deteriorating and timely consultation with an experienced center. This evidence fits the conference’s focus on ECMO capacity-building beyond metro centres and on realistic referral networks for complex respiratory failure.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
